

Notice of Changes to 340B Prices
11/29/2022

Pursuant to 42 C.F.R. § 447.510(b), Eli Lilly and Company (Lilly) has submitted routine updated 3Q2019 Average Manufacturer Prices and Best Prices for certain of its covered outpatient drugs to the Centers for Medicare & Medicare Services (CMS) to account for lagged transactional data. These restated Medicaid prices result in both upward and downward adjustments to 1Q2020 340B Ceiling Prices.

Table 1: Products Subject to Upward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description
00002446234	CIALIS 5 MG 30.000000 TABLET
00002446230	CIALIS 5MG 30.000000 TA
00002814801	HUMATROPE 12 MG 1.000000 MILLILITER
00002814901	HUMATROPE 24 MG 1.000000 MILLILITER
00002733511	HUMATROPE 5MG 1 MILLILITER
00002814701	HUMATROPE 6 MG 1.000000 MILLILITER
00002325130	STRATTERA 100MG 30.000000 CAP
00002323830	STRATTERA 18 MG 30.000000
00002322830	STRATTERA 25 MG 30.000000
00002323930	STRATTERA 60 MG 30.000000
00002143380	TRULICITY 0.75 MG 2.000000 MILLILITER
00002143480	TRULICITY 1.5MG 2.000000 MML

Lilly has elected not to seek recoupment of these underpayments from Covered Entities.

Table 2: Products Subject to Downward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description
00002446534	CIALIS 2.5MG 30.000000 TA
00002449108	REYVOW 100 MG 8.000000 TABLET
00002431208	REYVOW 50 MG 8.000000 TABLET
00002322730	STRATTERA 10 MG 30.000000
00002322930	STRATTERA 40 MG 30.000000
00002325030	STRATTERA 80MG 30.000000 CAP

Lilly uses wholesaler chargeback records to calculate and automatically issue refund payments to impacted eligible Covered Entities at the address listed in the HRSA database.

Lilly does not directly contact or automatically issue checks to Covered Entities who may be eligible for amounts less than \$1.00 resulting from this restatement. For these de minimis

changes, Lilly is offering to refund such Covered Entities through this Notice.

Covered Entities who believe they may be entitled to a refund amount less than \$1.00 for purchases of the above listed products in 1Q2020 or have questions about refunds Lilly already issued may contact Lilly at basesupport_cma@lilly.com with “Attn: 340B Recalculation” in the subject line to confirm any applicable amounts at issue and to initiate the payment process.

Lilly has requested that the Health Resource and Services Administration (HRSA) post this Notice on the HRSA public website to ensure transparency to Covered Entities regarding Lilly’s recalculation and refund process.
